- Home
- ANIX vs ONCY Comparison
ANIX vs ONCY Comparison
Compare ANIX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ONCY
- Stock Information
- Founded
- ANIX 1982
- ONCY 1998
- Country
- ANIX United States
- ONCY Canada
- Employees
- ANIX N/A
- ONCY N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- ANIX Health Care
- ONCY Health Care
- Exchange
- ANIX Nasdaq
- ONCY Nasdaq
- Market Cap
- ANIX 108.9M
- ONCY 49.1M
- IPO Year
- ANIX 1987
- ONCY 1999
- Fundamental
- Price
- ANIX $3.14
- ONCY $1.17
- Analyst Decision
- ANIX Strong Buy
- ONCY Strong Buy
- Analyst Count
- ANIX 3
- ONCY 4
- Target Price
- ANIX $9.00
- ONCY $4.33
- AVG Volume (30 Days)
- ANIX 127.9K
- ONCY 1.6M
- Earning Date
- ANIX 09-05-2025
- ONCY 07-31-2025
- Dividend Yield
- ANIX N/A
- ONCY N/A
- EPS Growth
- ANIX N/A
- ONCY N/A
- EPS
- ANIX N/A
- ONCY N/A
- Revenue
- ANIX N/A
- ONCY N/A
- Revenue This Year
- ANIX N/A
- ONCY N/A
- Revenue Next Year
- ANIX N/A
- ONCY N/A
- P/E Ratio
- ANIX N/A
- ONCY N/A
- Revenue Growth
- ANIX N/A
- ONCY N/A
- 52 Week Low
- ANIX $2.07
- ONCY $0.33
- 52 Week High
- ANIX $4.20
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- ANIX 48.32
- ONCY 75.27
- Support Level
- ANIX $3.18
- ONCY $0.71
- Resistance Level
- ANIX $3.24
- ONCY $1.31
- Average True Range (ATR)
- ANIX 0.16
- ONCY 0.12
- MACD
- ANIX -0.05
- ONCY 0.04
- Stochastic Oscillator
- ANIX 15.56
- ONCY 81.33
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.